Grifols SA (NASDAQ:GRFS) was upgraded by Zacks Investment Research from a “sell” rating to a “buy” rating in a note issued to investors on Wednesday. The firm currently has a $18.00 price objective on the stock. Zacks Investment Research’s target price suggests a potential upside of 12.29% from the stock’s current price.
According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “
Separately, Morgan Stanley reissued a “sell” rating on shares of Grifols SA in a research report on Monday, June 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $20.25.
Grifols SA (NASDAQ:GRFS) traded down 0.37% during midday trading on Wednesday, reaching $16.03. The company had a trading volume of 357,696 shares. The firm has a 50-day moving average of $16.25 and a 200-day moving average of $16.01. The stock has a market cap of $21.91 billion, a P/E ratio of 36.56 and a beta of 0.94. Grifols SA has a 12 month low of $14.07 and a 12 month high of $18.04.
Several institutional investors have recently bought and sold shares of the stock. Hansberger Growth Investors LP increased its position in Grifols SA by 2.6% in the second quarter. Hansberger Growth Investors LP now owns 90,273 shares of the company’s stock valued at $1,505,000 after buying an additional 2,253 shares during the last quarter. Fiera Capital Corp purchased a new position in Grifols SA during the second quarter valued at approximately $890,000. FDx Advisors Inc. increased its position in Grifols SA by 4.9% in the second quarter. FDx Advisors Inc. now owns 58,284 shares of the company’s stock valued at $972,000 after buying an additional 2,743 shares during the last quarter. Capital Guardian Trust Co. increased its position in Grifols SA by 2.2% in the second quarter. Capital Guardian Trust Co. now owns 421,336 shares of the company’s stock valued at $7,024,000 after buying an additional 9,103 shares during the last quarter. Finally, Walleye Trading LLC increased its position in Grifols SA by 31.0% in the second quarter. Walleye Trading LLC now owns 9,300 shares of the company’s stock valued at $155,000 after buying an additional 2,200 shares during the last quarter. 20.18% of the stock is currently owned by institutional investors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Grifols SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols SA and related companies with MarketBeat.com's FREE daily email newsletter.